Original Article
Brief Report
Atrial Natriuretic Peptide Frameshift Mutation in Familial Atrial Fibrillation
N Engl J Med 2008; 359:158-165July 10, 2008
- Abstract
Atrial fibrillation is a common arrhythmia that is hereditary in a small subgroup of patients. In a family with 11 clinically affected members, we mapped an atrial fibrillation locus to chromosome 1p36-p35 and identified a heterozygous frameshift mutation in the gene encoding atrial natriuretic peptide. Circulating chimeric atrial natriuretic peptide (ANP) was detected in high concentration in subjects with the mutation, and shortened atrial action potentials were seen in an isolated heart model, creating a possible substrate for atrial fibrillation. This report implicates perturbation of the atrial natriuretic peptide–cyclic guanosine monophosphate (cGMP) pathway in cardiac electrical instability.
Media in This Article
Figure 1
Pedigree of a Family with Hereditary Atrial Fibrillation.Figure 2
Radioimmunoassay Analysis Showing the Presence of Mutant ANP in Plasma from Heterozygotes for the NPPA Mutation.Article Activity
- Article
Atrial fibrillation is the most common sustained cardiac arrhythmia. Since the lifetime risk of the condition is 25%, it constitutes a growing epidemic in the aging population.1,2 Atrial fibrillation develops as a paroxysmal disorder characterized by rapid, irregular electrical activation of the atria and can be associated with palpitations, syncope, thromboembolic stroke, and congestive heart failure. Valvular, ischemic, hypertensive, and myopathic heart diseases are the most common causes of acquired atrial fibrillation. However, a genetic basis for atrial fibrillation is evident in population-based studies3,4 and in a subgroup of patients with familial disease.5,6 Human genetics investigations have identified atrial fibrillation–associated mutations in cardiac ion channels7-9 and gap junction proteins,10 findings that implicate myocellular derangements in ion flux. However, the molecular basis of atrial fibrillation remains unknown in a majority of cases. We used linkage analysis to identify a novel mutation in the natriuretic peptide precursor A gene (NPPA), which encodes ANP. This mutation segregates with familial atrial fibrillation, thereby uncovering an unexpected association between a defect in a circulating hormone and susceptibility to arrhythmia.
Methods
Study Subjects
We studied members of a white family of northern European ancestry who had atrial fibrillation segregating as an autosomal dominant trait (Figure 1Figure 1
Pedigree of a Family with Hereditary Atrial Fibrillation.). In addition, we randomly selected a group of 560 control subjects from a population-based white cohort of northern European ancestry who had normal results on electrocardiography and echocardiography. Family members and control subjects provided written informed consent under a research protocol approved by the institutional review board at the Mayo Clinic.We reviewed medical records of all the study subjects. The phenotypic classification of a subject as having familial atrial fibrillation (“affected”) required documentation of atrial fibrillation on electrocardiography and the absence of clinical risk factors for arrhythmia, such as uncontrolled hypertension and primary structural heart disease. Subjects with normal findings on electrocardiography who did not have symptoms of frequent palpitations, racing heart rate, dizziness, or syncope were classified as “unaffected.”
For genetic analysis, genomic DNA was isolated from peripheral-blood white cells. For protein studies, additional blood samples were obtained from three family members. Samples were collected in EDTA tubes and centrifuged at 2500 rpm at 4°C for 10 minutes.
Linkage Analysis and Mapping
For primary genome scanning, we used the ABI PRISM Linkage Mapping Set MD10, version 2.5 (Applied Biosystems), which consisted of fluorescently labeled polymerase-chain-reaction (PCR) primer pairs for 400 tandem repeat markers with average spacing of 10 cM. After PCR amplification of genomic DNA samples, amplified fragments were resolved on an ABI PRISM 3100 Genetic Analyzer and analyzed with GeneScan Analysis and Genotyper software. Two-point and multipoint linkage analyses were performed with the use of the FASTLINK program and specification of the following variables: a disease allele frequency of 0.001, a phenocopy rate of 0.001, equal marker allele frequencies, and dichotomous liability classes (“affected” and “unaffected”). Lod scores were determined for affected subjects only and for 80% and 100% penetrance models at recombination frequencies of 0.0 to 0.4.
Fine mapping was performed with additional closely spaced microsatellite markers that were localized on genetic and physical maps, accessible on the Web site of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). Genotyping was accomplished by PCR amplification of genomic DNA radiolabeled with [α-32P] deoxycytidine triphosphate, resolution of alleles by polyacrylamide-gel electrophoresis, and visualization by autoradiography. Scored genotypes were assembled as haplotypes to define the critical region of complete linkage on the basis of recombination events in affected subjects.
Mutation Detection
Primer pairs for exon-specific PCR amplification of the three translated exons of NPPA were designed with the use of Oligo Primer Analysis Software, version 6.51 (National Biosciences) (for details, see the Supplementary Appendix, available with the full text of this article at www.nejm.org). Amplified products were treated with the PCR Product Presequencing Kit (USB) and sequenced by the dye-terminator method in a core facility with the use of an ABI PRISM 3730 XL DNA Analyzer (Applied Biosystems). DNA sequences were viewed and analyzed with the Sequencher computer program (Gene Codes), and a mutation was identified that segregated with atrial fibrillation. For single-allele sequencing of DNA from heterozygotes, the mutant allele was separated from the wild-type allele by polyacrylamide-gel electrophoresis. Samples from control subjects were screened for the mutation by denaturing high-performance liquid chromatography heteroduplex analysis with the use of the WAVE DNA fragment analysis system (Transgenomic).
Mutant ANP Peptide and Antibody
A custom-designed polyclonal antibody against the mutant form of ANP (mANP) was manufactured commercially (21st Century Biochemicals). The peptide Ac-CYRITAREDKQGWA-OH, corresponding to the anomalous residues of mANP, was synthesized, purified to 96% by high-performance liquid chromatography, and verified by peptide sequencing and mass spectroscopy. Conjugated peptide was injected into rabbits, serving as an epitope for the generation of affinity-purified polyclonal antibody. Full-length mANP (with 40 amino acids) was synthesized in a core facility for use in developing the mANP radioimmunoassay and for the experiments with isolated hearts.
Radioimmunoassay
Radioimmunoassays were developed for both mANP (with the use of the polyclonal antibody described above) and for wild-type ANP (with the use of commercially available antibody [Phoenix Pharmaceuticals]). Technical details are provided in the Supplementary Appendix. Both antibodies were labeled with iodine-125.
The binding specificity of anti-mANP antibody was demonstrated by first generating standard curves with varying amounts of synthetic mANP and then measuring samples from the subjects at several dilutions to assess cross-reactivity. Standard curves were generated for calculating the ANP and mANP concentrations, in picograms per milliliter, in samples from both family members and control subjects. The range of the standard curve was 2 to 500 pg per milliliter for both ANP and mANP. All peptide measurements were made in duplicate, and values were reported as the average of the two. The normal range for ANP on the basis of this assay was determined to be 14 to 36 pg per milliliter among 100 samples.
A commercially available immunoradiometric assay was used to measure B-type natriuretic peptide (BNP) concentrations (Shionogi) (see the Supplementary Appendix). A calibration curve (range, 0 to 2000 pg per milliliter) was constructed from standard BNP solutions to estimate BNP concentrations in the samples. The normal range for BNP with the use of this assay was determined to be 8 to 16 pg per milliliter among 100 samples.
Isolated-Heart Model
The institutional animal care and use committee at the University of Iowa approved all the procedures for studies in animals. Atrial monophasic action potentials and effective refractory periods were measured in isolated, perfused hearts obtained from male rats. Each set of measurements was performed in separate isolated hearts. Details of the preparation of the isolated hearts are provided in the Supplementary Appendix.
After establishment of a stable perfused-heart preparation, the posterior atria were cut away to expose the left and right atrial endocardium, and the atrioventricular node was mechanically crushed, resulting in atrioventricular dissociation. The right atrium was paced with a Bloom Electrophysiology Stimulator (Fischer Medical Technologies) at a cycle length of 150 msec and a pulse width of 0.1-msec with the use of a bipolar platinum-tipped electrode (NuMed), and the right ventricle was paced at a cycle length of 500 msec. A monophasic action potential (MAP) probe (Harvard Apparatus) was maintained in a single position on the anterior left atrial endocardium. Amplified signals (IsoDam, World Precision Instruments) were digitally acquired at 2 kHz (USB-6210 and LabVIEW 8.2, National Instruments). The MAP duration was measured at 90% repolarization on atrial beats without far-field ventricular interference. The effective refractory period was measured by delivering extrastimuli through the pacing catheter at decremental coupling intervals after at least 8 beats of a drive train with a 150-msec cycle length. The effective refractory period was defined as the longest extrastimulus coupling interval that did not result in a propagated response, as measured by the left atrial MAP probe. In separate heart preparations, the perfusion buffer was supplemented after baseline data acquisition with 100 nM of either ANP or mANP to assess the effect of both the wild-type and mutant hormones on MAP duration and the effective refractory period.
Statistical Analysis
We used a two-sided t-test for the comparison of data, assuming equal variance. Data are expressed as means (±SE); P values below 0.05 were considered to indicate statistical significance.
Results
Case Subjects
We collected clinical data for 16 members of the family (Figure 1 and Table 1Table 1
Phenotypic Data for Members of a Family with Autosomal Dominant Atrial Fibrillation.). Eleven affected family members had received a diagnosis of familial atrial fibrillation at a mean age of 40 years; of these subjects, three had received the diagnosis during pregnancy. Transition from paroxysmal to chronic atrial fibrillation (in three of the subjects) or to arrest of atrial activation (in four of the subjects) suggested progressive electrical remodeling. Five subjects presented with tachycardia-induced cardiomyopathy, which improved or resolved with effective pharmacologic rate control. Subsequent echocardiography ruled out cardiac hypertrophy and contractile dysfunction but showed dilatation of the left atrial chamber in seven subjects and of the left ventricular chamber in four subjects.NPPA Mutation
Genomewide linkage analyses ruled out known loci for atrial fibrillation and identified peak two-point lod scores at marker D1S2667, ranging from 2.32 (in the analysis of only affected subjects) to 3.56 (in the analysis of all subjects, assuming 100% mutation penetrance) at a recombination frequency of 0%. Fine mapping identified a disease-associated haplotype on chromosome 1p36-p35, a region spanning 24 Mb that was inherited by all affected subjects (peak multipoint lod scores, 2.66 for affected subjects only and 3.90 for all subjects, assuming 100% mutation penetrance) (Figure 1). A recombination event within this interval in a 38-year-old asymptomatic man (Subject III-9), if it was assumed that he did not inherit the disease-associated mutation, further narrowed the critical region to 11 Mb.
We selected NPPA as a candidate gene because of its localization in the mapped interval, its expression in the atria of the heart, and its established role in cardiovascular physiology.11,12 We excluded seven other genes, including two — solute carrier family 9, member 1 (SLC9A1) and chloride intracellular channel 4 (CLIC4) — that have direct roles in ion regulation. Genomic DNA sequencing of NPPA identified a two-base-pair deletion (c.456-457delAA) in exon 3 that causes a frameshift, which abolishes the stop codon and extends the reading frame. Translation of the mutant gene would generate a fusion protein comprising the normal mature peptide containing 28 amino acids plus an anomalous carboxyl terminus of 12 residues (for details, see the Supplementary Appendix). Each of the 11 clinically affected family members was heterozygous for the mutation; the mutation was absent in the other 5 family members and in 560 control subjects.
Mutant Peptide
Radioimmunoassay showed that the mutant peptide was present in the plasma of heterozygotes in concentrations that were higher by a factor of 5 to 10 than the concentrations of wild-type ANP (Figure 2Figure 2
Radioimmunoassay Analysis Showing the Presence of Mutant ANP in Plasma from Heterozygotes for the NPPA Mutation.). Anti-ANP antibody was found to be specific for wild-type ANP, since the aberrant carboxyl tail of mANP apparently prevented binding of this antibody. BNP levels were normal, which was consistent with an absence of overt ventricular disease.12 To determine the integrative electrophysiological effects of circulating mANP on the heart, an isolated whole-heart model was studied. As compared with wild-type ANP, mANP caused significant shortening of the MAP duration and the effective refractory period (Figure 3Figure 3
Electrophysiological Effects of Circulating Mutant ANP in a Rat Isolated Whole-Heart Model.).Discussion
ANP is a circulating hormone that, through stimulation of the intracellular second messenger cGMP, plays a primary physiological role in the regulation of intravascular blood volume and vascular tone through natriuresis, diuresis, and vasodilatation.12 Through cGMP signaling, ANP also modulates currents of sodium, calcium, and potassium channels in cardiac myocytes.13-15 Moreover, in atria of intact human hearts, ANP has been shown to shorten atrial conduction time and the effective refractory period, which provides a potential electrophysiological substrate for arrhythmia.16 ANP has also been shown to cause dose-dependent, autonomically mediated shortening of the atrial MAP duration and the effective refractory period in dogs.17 Thus, the suggestion that a mutation in NPPA could be responsible for the development of atrial fibrillation is consistent with some of the known aspects of ANP physiology.
To elucidate the mechanism by which a mutation in NPPA could lead to familial atrial fibrillation, we first showed that the mutation we identified results in the production of a mutant protein product. The concentration of circulating mANP was several times as high as that of wild-type ANP. One possible explanation for this difference in concentration is that mANP may have a prolonged half-life. Indeed, natriuretic peptides with a longer carboxyl terminus have increased resistance to degradation by neutral endopeptidase 24.11.18 In particular, Dendroaspis augusticeps natriuretic peptide (DNP), a unique natriuretic peptide isolated from snake venom, has a carboxyl-terminal extension of 15 amino acids and increased cGMP-stimulating potency.18,19 The phenotype that we observed in family members could thus be explained by high levels of circulating mANP with ANP-like activity. Such a mechanism would be consistent with previous experimental studies showing electrophysiological derangements on exposure of atrial myocytes to pathophysiological doses of ANP.14-17 Moreover, the mild structural remodeling, despite effective ventricular rate control, in several affected members of the family we studied is consistent with a proapoptotic effect on myocytes observed with excessive ANP–cGMP signaling.20 However, regardless of potential dose-related and structural remodeling effects, our isolated (denervated) heart model showed a direct effect of mANP, but not wild-type ANP, on atrial electrophysiology. Although an additional novel function of the mANP fusion protein cannot be ruled out, the 12-residue carboxyl terminus has no strong sequence homology with known proteins. Atrial fibrillation developed in affected subjects over a period of several decades, as observed in patients with primary defects in ion channels and gap junctions,7-10 which suggests insidious but progressive electrical remodeling that conferred susceptibility to atrial arrhythmia.
The linkage analysis we performed has some limitations. Several subjects in the family who were classified as “unaffected” had not yet reached the mean age at which atrial fibrillation was diagnosed in other family members. If the analysis is based only on the family members who were known to be affected, the lod score was 2.66, which is below the threshold of 3.0 commonly accepted to confirm linkage. However, the fact that the mutation in the gene encoding ANP segregates with known disease and the demonstration that mANP has electrophysiological effects that could confer a predisposition to atrial fibrillation strongly suggest that we have correctly identified the causative mutation.
In families with atrial fibrillation, investigators have identified mutations in ion channels that are predicted to either shorten or lengthen the duration of cardiac action potentials.21 Our findings uncover a novel molecular genetic basis for abnormal repolarization and electrical instability in the cardiac atria and suggest the ANP–cGMP signaling pathway as a potentials therapeutic target.22,23
Supported by grants (R01 HL075495, to Dr. Olson, and P01 HL76611 and R01 HL36634, to Dr. Burnett) from the National Institutes of Health and an award from the Mayo Foundation (to Dr. Olson).
Dr. Burnett reports serving on an advisory board at Nile Therapeutics and receiving lecture fees from Scios. No other potential conflict of interest relevant to this article was reported.
Source Information
From the Department of Internal Medicine, University of Iowa, Carver College of Medicine, Iowa City (D.M.H-Z., L.V.Z.); and the Cardiovascular Genetics Laboratory, Departments of Internal Medicine (M.L.K., D.D., K.J.H., J.D.B., T.M.O.) and Pediatric and Adolescent Medicine (T.M.O.), the Cardiorenal Research Laboratory, Departments of Physiology and Internal Medicine (D.M.H., J.C.B.), and the Department of Health Sciences Research (M.A.) — all at the College of Medicine, Mayo Clinic, Rochester, MN.
Address reprint requests to Dr. Olson at Mayo Clinic, 200 First St. SW, Rochester, MN 55905, or at olson.timothy@mayo.edu.
- References
References
1
Braunwald E . Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-1369
Full Text | Web of Science | Medline2
Lloyd-Jones DM ,Wang TJ ,Leip EP , et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-1046
CrossRef | Web of Science | Medline3
Fox CS ,Parise H ,D'Agostino RB , et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-2855
CrossRef | Web of Science | Medline4
Gudbjartsson DF ,Arnar DO ,Helgadottir A , et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-357
CrossRef | Web of Science | Medline5
Brugada R ,Tapscott T ,Czernuszewicz GZ , et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997;336:905-911
Full Text | Web of Science | Medline6
Darbar D ,Herron KJ ,Ballew JD , et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003;41:2185-2192
CrossRef | Web of Science | Medline7
Chen YH ,Xu SJ ,Bendahhou S , et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251-254
CrossRef | Web of Science | Medline8
Olson TM ,Michels VV ,Ballew JD , et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005;293:447-454
CrossRef | Web of Science | Medline9
Olson TM ,Alekseev AE ,Liu XK , et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185-2191
CrossRef | Web of Science | Medline10
Gollob MH ,Jones DL ,Krahn AD , et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006;354:2677-2688
Full Text | Web of Science | Medline11
Burnett JC Jr ,Kao PC ,Hu DC , et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-1147
CrossRef | Web of Science | Medline12
Levin ER ,Gardner DG ,Samson WK . Natriuretic peptides. N Engl J Med 1998;339:321-328
Full Text | Web of Science | Medline13
Sorbera LA ,Morad M . Atrionatriuretic peptide transforms cardiac sodium channels into calcium-conducting channels. Science 1990;247:969-973
CrossRef | Web of Science | Medline14
Le Grand B ,Deroubaix E ,Couetil JP ,Coraboeuf E . Effects of atrionatriuretic factor on Ca2+ current and Cai-independent transient outward K+ current in human atrial cells. Pflugers Arch 1992;421:486-491
CrossRef | Web of Science | Medline15
Lonardo G ,Cerbai E ,Casini S , et al. Atrial natriuretic peptide modulates the hyperpolarization-activated current (If) in human atrial myocytes. Cardiovasc Res 2004;63:528-536
CrossRef | Web of Science | Medline16
Crozier I ,Richards AM ,Foy SG ,Ikram H . Electrophysiological effects of atrial natriuretic peptide on the cardiac conduction system in man. Pacing Clin Electrophysiol 1993;16:738-742
CrossRef | Web of Science | Medline17
Stambler BS ,Guo GB . Atrial natriuretic peptide has dose-dependent, autonomically mediated effects on atrial refractoriness and repolarization in anesthetized dogs. J Cardiovasc Electrophysiol 2005;16:1341-1347
CrossRef | Web of Science | Medline18
Chen HH ,Lainchbury JG ,Burnett JC Jr . Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002;40:1186-1191
CrossRef | Web of Science | Medline19
Johns DG ,Ao Z ,Heidrich BJ , et al. Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem Biophys Res Commun 2007;358:145-149
CrossRef | Web of Science | Medline20
Kato T ,Muraski J ,Chen Y , et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005;115:2716-2730
CrossRef | Web of Science | Medline21
Fatkin D ,Otway R ,Vandenberg JI . Genes and atrial fibrillation: a new look at an old problem. Circulation 2007;116:782-792
CrossRef | Web of Science | Medline22
Potter LR ,Abbey-Hosch S ,Dickey DM . Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47-72
CrossRef | Web of Science | Medline23
Murad F . Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006;355:2003-2011
Full Text | Web of Science | Medline
- Citing Articles (43)
Citing Articles
1
Paul M. McKie, Tomoko Ichiki, John C. Burnett. (2012) M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy. Current Hypertension Reports 14:1, 62-69
CrossRef2
S. W. Dubrey, R. L. Comenzo. (2012) Amyloid diseases of the heart: current and future therapies. QJM
CrossRef3
Xinyuan Liu, Fei Wang, Ashley C. Knight, Jiangmin Zhao, Junjie Xiao. (2012) Common variants for atrial fibrillation: results from genome-wide association studies. Human Genetics 131:1, 33-39
CrossRef4
Renate B. Schnabel. (2012) Can We Predict the Occurrence of Atrial Fibrillation?. Clinical Cardiology 35:S1, S5-S9
CrossRef5
Babar Parvez, Dawood Darbar. (2011) The “missing” link in atrial fibrillation heritability. Journal of Electrocardiology 44:6, 641-644
CrossRef6
Mark J. Perrin, Michael H. Gollob. (2011) The role of atrial natriuretic peptide in modulating cardiac electrophysiology. Heart Rhythm
CrossRef7
Junjie Xiao, Dandan Liang, Yi-Han Chen. (2011) The Genetics of Atrial Fibrillation: From the Bench to the Bedside. Annual Review of Genomics and Human Genetics 12:1, 73-96
CrossRef8
Shinsuke Miyazaki, Ashok J. Shah, Daniel Scherr, Michel Haïssaguerre. (2011) Atrial fibrillation: Pathophysiology and current therapy. Annals of Medicine 43:6, 425-436
CrossRef9
Yi-Qing Yang, Mao-Ya Wang, Xian-Ling Zhang, Hong-Wei Tan, Hai-Feng Shi, Wei-Feng Jiang, Xin-Hua Wang, Wei-Yi Fang, Xu Liu. (2011) GATA4 loss-of-function mutations in familial atrial fibrillation. Clinica Chimica Acta 412:19-20, 1825-1830
CrossRef10
M. J. Ackerman, S. G. Priori, S. Willems, C. Berul, R. Brugada, H. Calkins, A. J. Camm, P. T. Ellinor, M. Gollob, R. Hamilton, R. E. Hershberger, D. P. Judge, H. Le Marec, W. J. McKenna, E. Schulze-Bahr, C. Semsarian, J. A. Towbin, H. Watkins, A. Wilde, C. Wolpert, D. P. Zipes. (2011) HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 13:8, 1077-1109
CrossRef11
Michael J. Ackerman, Silvia G. Priori, Stephan Willems, Charles Berul, Ramon Brugada, Hugh Calkins, A. John Camm, Patrick T. Ellinor, Michael Gollob, Robert Hamilton, Ray E. Hershberger, Daniel P. Judge, Hervè Le Marec, William J. McKenna, Eric Schulze-Bahr, Chris Semsarian, Jeffrey A. Towbin, Hugh Watkins, Arthur Wilde, Christian Wolpert, Douglas P. Zipes. (2011) HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm 8:8, 1308-1339
CrossRef12
Deborah M. Dickey, Lincoln R. Potter. (2011) Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. Journal of Molecular and Cellular Cardiology 51:1, 67-71
CrossRef13
Adele H. Goodloe, Kathleen J. Herron, Timothy M. Olson. (2011) Uncovering an Intermediate Phenotype Associated With rs2200733 at 4q25 in Lone Atrial Fibrillation. The American Journal of Cardiology 107:12, 1802-1805
CrossRef14
Lincoln R. Potter. (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS Journal 278:11, 1808-1817
CrossRef15
S. Mahida, S. A. Lubitz, M. Rienstra, D. J. Milan, P. T. Ellinor. (2011) Monogenic atrial fibrillation as pathophysiological paradigms. Cardiovascular Research 89:4, 692-700
CrossRef16
Michael H. Gollob. (2011) The evolution of gene discovery and the revelation of truth. Heart Rhythm 8:3, 410-411
CrossRef17
Cong Li, Fan Wang, Yanzong Yang, Fenfen Fu, Chengqi Xu, Lisong Shi, Sisi Li, Yunlong Xia, Gang Wu, Xiang Cheng, Hui Liu, Chuchu Wang, Pengyun Wang, Jianjun Hao, Yuhe Ke, Yuanyuan Zhao, Mugen Liu, Rongfeng Zhang, Lianjun Gao, Bo Yu, Qiutang Zeng, Yuhua Liao, Bo Yang, Xin Tu, Qing K. Wang. (2011) Significant association of SNP rs2106261 in the ZFHX3 gene with atrial fibrillation in a Chinese Han GeneID population. Human Genetics 129:3, 239-246
CrossRef18
Robin Lemmens, Sylvia Hermans, Dieter Nuyens, Vincent Thijs. (2011) Genetics of Atrial Fibrillation and Possible Implications for Ischemic Stroke. Stroke Research and Treatment 2011, 1-7
CrossRef19
Y.-Q. Yang, X. Liu, X.-L. Zhang, X.-H. Wang, H.-W. Tan, H.-F. Shi, W.-F. Jiang, W.-Y. Fang. (2010) Novel connexin40 missense mutations in patients with familial atrial fibrillation. Europace 12:10, 1421-1427
CrossRef20
P. Kirchhof, L. Fabritz, K. Tiemann. (2010) An ultrasound view on the substrate for incident and recurrent atrial fibrillation in heart failure patients. European Journal of Heart Failure 12:10, 1019-1020
CrossRef21
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:10, 1360-1420
CrossRef22
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31:19, 2369-2429
CrossRef23
J. D. Roberts, R. W. Davies, S. A. Lubitz, I. L. Thibodeau, P. B. Nery, D. H. Birnie, E. J. Benjamin, R. Lemery, P. T. Ellinor, M. H. Gollob. (2010) Evaluation of non-synonymous NPPA single nucleotide polymorphisms in atrial fibrillation. Europace 12:8, 1078-1083
CrossRef24
Pengyun Wang, Qinbo Yang, Xiaofen Wu, Yanzong Yang, Lisong Shi, Chuchu Wang, Gang Wu, Yunlong Xia, Bo Yang, Rongfeng Zhang, Chengqi Xu, Xiang Cheng, Sisi Li, Yuanyuan Zhao, Fenfen Fu, Yuhua Liao, Fang Fang, Qiuyun Chen, Xin Tu, Qing K. Wang. (2010) Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population. Biochemical and Biophysical Research Communications 398:1, 98-104
CrossRef25
Fernando D. Testai, Philip B. Gorelick. (2010) New Approaches to Stroke Prevention in Atrial Fibrillation. Current Treatment Options in Cardiovascular Medicine 12:3, 261-273
CrossRef26
J. Wang, E. Klysik, S. Sood, R. L. Johnson, X. H. T. Wehrens, J. F. Martin. (2010) Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proceedings of the National Academy of Sciences 107:21, 9753-9758
CrossRef27
Oscar Campuzano, Pedro Beltrán-Álvarez, Anna Iglesias, Fabiana Scornik, Guillermo Pérez, Ramon Brugada. (2010) Genetics and cardiac channelopathies. Genetics in Medicine 12:5, 260-267
CrossRef28
M Khaled Sabeh, Calum A MacRae. (2010) The genetics of atrial fibrillation. Current Opinion in Cardiology 25:3, 186-191
CrossRef29
Xiang Ren, Chengqi Xu, Chengxiong Zhan, Yanzong Yang, Lisong Shi, Fan Wang, Chuchu Wang, Yunlong Xia, Bo Yang, Gang Wu, Pengyun Wang, Xiuchun Li, Dan Wang, Xin Xiong, Jinqiu Liu, Ying Liu, Mugen Liu, Jingyu Liu, Xin Tu, Qing Kenneth Wang. (2010) Identification of NPPA variants associated with atrial fibrillation in a Chinese GeneID population. Clinica Chimica Acta 411:7-8, 481-485
CrossRef30
Jason D. Roberts, Michael H. Gollob. (2010) Impact of Genetic Discoveries on the Classification of Lone Atrial Fibrillation. Journal of the American College of Cardiology 55:8, 705-712
CrossRef31
Stéphane N. Hatem, Alain Coulombe, Elise Balse. (2010) Specificities of atrial electrophysiology: Clues to a better understanding of cardiac function and the mechanisms of arrhythmias. Journal of Molecular and Cellular Cardiology 48:1, 90-95
CrossRef32
Robert L. Abraham, Tao Yang, Marcia Blair, Dan M. Roden, Dawood Darbar. (2010) Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. Journal of Molecular and Cellular Cardiology 48:1, 181-190
CrossRef33
H. Le Marec, V. Probst. (2009) Génétique de la fibrillation auriculaire. Annales de Cardiologie et d'Angéiologie 58, S70-S72
CrossRef34
Lisong Shi, Cong Li, Chuchu Wang, Yunlong Xia, Gang Wu, Fan Wang, Chengqi Xu, Pengyun Wang, Xiuchun Li, Dan Wang, Xin Xiong, Ying Bai, Mugen Liu, Jingyu Liu, Xiang Ren, Lianjun Gao, Binbin Wang, Qiutang Zeng, Bo Yang, Xu Ma, Yanzong Yang, Xin Tu, Qing Kenneth Wang. (2009) Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. Human Genetics 126:6, 843-849
CrossRef35
O. Campuzano, R. Brugada. (2009) Genetics of familial atrial fibrillation. Europace 11:10, 1267-1271
CrossRef36
Adolfo J. de Bold. (2009) Cardiac Natriuretic Peptides. Journal of the American College of Cardiology 54:11, 1033-1034
CrossRef37
Paul M. McKie, Alessandro Cataliotti, Brenda K. Huntley, Fernando L. Martin, Timothy M. Olson, John C. Burnett. (2009) A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel Peptide With Enhanced Blood Pressure-Lowering, Renal-Enhancing, and Aldosterone-Suppressing Actions. Journal of the American College of Cardiology 54:11, 1024-1032
CrossRef38
Emelia J Benjamin, Kenneth M Rice, Dan E Arking, Arne Pfeufer, Charlotte van Noord, Albert V Smith, Renate B Schnabel, Joshua C Bis, Eric Boerwinkle, Moritz F Sinner, Abbas Dehghan, Steven A Lubitz, Ralph B D'Agostino Sr, Thomas Lumley, Georg B Ehret, Jan Heeringa, Thor Aspelund, Christopher Newton-Cheh, Martin G Larson, Kristin D Marciante, Elsayed Z Soliman, Fernando Rivadeneira, Thomas J Wang, Gudny Eiríksdottir, Daniel Levy, Bruce M Psaty, Man Li, Alanna M Chamberlain, Albert Hofman, Ramachandran S Vasan, Tamara B Harris, Jerome I Rotter, W H Linda Kao, Sunil K Agarwal, Bruno H Ch Stricker, Ke Wang, Lenore J Launer, Nicholas L Smith, Aravinda Chakravarti, André G Uitterlinden, Philip A Wolf, Nona Sotoodehnia, Anna Köttgen, Cornelia M van Duijn, Thomas Meitinger, Martina Mueller, Siegfried Perz, Gerhard Steinbeck, H-Erich Wichmann, Kathryn L Lunetta, Susan R Heckbert, Vilmundur Gudnason, Alvaro Alonso, Stefan Kääb, Patrick T Ellinor, Jacqueline C M Witteman. (2009) Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nature Genetics 41:8, 879-881
CrossRef39
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 11:7, 860-885
CrossRef40
Alex V. Postma, Lukas R.C. Dekker, Alexandre T. Soufan, Antoon F.M. Moorman. (2009) Developmental and Genetic Aspects of Atrial Fibrillation. Trends in Cardiovascular Medicine 19:4, 123-130
CrossRef41
Y. Zhou, J. Jiang, Y. Cui, Q. Wu. (2008) Corin, atrial natriuretic peptide and hypertension. Nephrology Dialysis Transplantation 24:4, 1071-1073
CrossRef42
Xianqin Zhang, Shenghan Chen, Shin Yoo, Susmita Chakrabarti, Teng Zhang, Tie Ke, Carlos Oberti, Sandro L. Yong, Fang Fang, Lin Li, Roberto de la Fuente, Lejin Wang, Qiuyun Chen, Qing Kenneth Wang. (2008) Mutation in Nuclear Pore Component NUP155 Leads to Atrial Fibrillation and Early Sudden Cardiac Death. Cell 135:6, 1017-1027
CrossRef43
Dawood Darbar. (2008) Cardiac sodium channel variants: Action players with many faces. Heart Rhythm 5:10, 1441-1443
CrossRef
